Elicio Therapeutics executives will discuss advancements in immunotherapy at the H.C. Wainwright Global Investment Conference on September 14, 2026.
Quiver AI Summary
Elicio Therapeutics, Inc., a biotechnology company focused on developing immunotherapies for KRAS-driven cancers, has announced that its CEO Robert Connelly and Chief Scientific Officer Pete DeMuth will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference from September 14-16, 2026, in New York City. The presentation will take place on September 14 at 2:00 PM ET, and interested parties can access a live webcast and replay on Elicio's Events page. Elicio is advancing its AMP technology to create effective off-the-shelf immunotherapies aimed at treating mKRAS-positive pancreatic and colorectal cancers, among others. Their lead candidate, ELI-002 7P, targets common KRAS mutations found in approximately 25% of solid tumors, promising lower costs and quicker availability compared to personalized therapies. The company's pipeline also includes candidates ELI-007 and ELI-008, targeting BRAF-driven cancers and p53 mutations, respectively. For additional information, visit Elicio's website.
Potential Positives
- Participation of Elicio's CEO and CSO in a prominent investment conference highlights the company's visibility and credibility in the biotechnology sector.
- Announcement of innovative off-the-shelf immunotherapies targeting KRAS-driven cancers demonstrates Elicio’s commitment to advancing cancer treatment options.
- Elicio's AMP technology aims to enhance T cell activation, potentially offering significant advancements over conventional immunotherapy approaches.
- Pipeline inclusion of additional targets like BRAF-driven cancers and p53 mutations indicates a broad and diversified approach to cancer immunotherapy development.
Potential Negatives
- Company is in the clinical stage, which may raise concerns about the effectiveness and safety of its therapies compared to established treatments.
- No concrete data or results from ongoing or completed clinical trials were provided, which might lead to skepticism from investors regarding the credibility and potential success of their therapies.
- The focus on a specific niche, KRAS-driven cancers, may limit market opportunities and increase vulnerability to competition in the oncology landscape.
FAQ
What is Elicio Therapeutics focused on?
Elicio Therapeutics develops next-generation immunotherapies for KRAS-driven cancers, including pancreatic and colorectal cancers.
When will Elicio participate in the H.C. Wainwright conference?
Elicio will participate in the conference on September 14, 2026, at 2:00 PM ET.
How can I access the Elicio conference presentation?
The live webcast and replay will be available on Elicio’s Events page for 90 days after the event.
What is the lead program of Elicio Therapeutics?
Elicio’s lead program, ELI-002, is an off-the-shelf immunotherapy targeting the most common KRAS mutations.
Who can I contact for a 1×1 meeting at the conference?
You can contact your H.C. Wainwright representative to arrange a 1×1 meeting with Elicio management.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ELTX Hedge Fund Activity
We have seen 36 institutional investors add shares of $ELTX stock to their portfolio, and 34 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 715,408 shares (+1413.9%) to their portfolio in Q2 2026, for an estimated $2,797,245
- KNOLL CAPITAL MANAGEMENT, LLC added 581,042 shares (+92.1%) to their portfolio in Q2 2026, for an estimated $2,271,874
- BALYASNY ASSET MANAGEMENT L.P. removed 244,814 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $957,222
- GEODE CAPITAL MANAGEMENT, LLC added 176,190 shares (+130.4%) to their portfolio in Q2 2026, for an estimated $688,902
- STATE STREET CORP added 128,800 shares (+254.4%) to their portfolio in Q2 2026, for an estimated $503,608
- RENAISSANCE TECHNOLOGIES LLC removed 121,631 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $475,577
- IKARIAN CAPITAL, LLC added 100,000 shares (+inf%) to their portfolio in Q2 2026, for an estimated $391,000
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$ELTX Price Targets
Multiple analysts have issued price targets for $ELTX recently. We have seen 5 analysts offer price targets for $ELTX in the last 6 months, with a median target of $20.0.
Here are some recent targets:
- Kevin DeGeeter from Ladenburg Thalmann set a target price of $12.0 on 06/18/2026
- Robert Burns from HC Wainwright & Co. set a target price of $23.0 on 06/15/2026
- Mayank Mamtani from B. Riley Securities set a target price of $27.0 on 06/10/2026
- Michael King from Rodman & Renshaw set a target price of $17.0 on 03/10/2026
Full Release
BOSTON, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that Robert Connelly, Chief Executive Officer and Pete DeMuth, PhD, Chief Scientific Officer, will participate in a fireside chat at the upcoming H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026, in New York, New York.
H.C. Wainwright 28th Annual Global Investment Conference
Format
: Fireside Chat
Date
: Monday, September 14, 2026
Time
: 2:00 PM ET
The live webcast and replay of the presentation will be available here and on Elicio’s Events page for 90 days following the event.
If you are interested in arranging a 1×1 meeting with management at the conference, please contact your H.C. Wainwright representative.
About Elicio Therapeutics
Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company advancing next-generation immunotherapies for the treatment of KRAS-driven cancers, including mKRAS-positive pancreatic and colorectal cancers. Elicio intends to build on recent clinical findings in the personalized cancer immunotherapy space to develop effective, off-the-shelf immunotherapies. Elicio’s AMP technology aims to enhance the education, activation, and amplification of cancer-specific T cells relative to conventional immunotherapy strategies, with the goal of promoting durable cancer immunosurveillance in patients. Elicio’s ELI-002 7P lead program is an off-the-shelf immunotherapy candidate targeting the most common KRAS mutations, which drive approximately 25% of all solid tumors. Off-the-shelf immunotherapy approaches have the potential benefits of low cost, rapid, commercial-scale manufacturing, and rapid availability of drug to patients, especially in neo-adjuvant settings and for prophylaxis in high-risk patients, contrary to personalized immunotherapy approaches. Elicio’s pipeline includes additional off-the-shelf therapeutic cancer immunotherapy candidates, including ELI-007 and ELI-008, which target BRAF-driven cancers and p53 hotspot mutations, respectively. For more information, please visit www.elicio.com .
Investor Relations Contact
Brian Ritchie
LifeSci Advisors
(212) 915-2578
[email protected]
